| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 196 | 2025 | 287 | 34.980 |
Why?
|
| Coronary Artery Disease | 122 | 2024 | 216 | 21.620 |
Why?
|
| Drug-Eluting Stents | 84 | 2024 | 102 | 16.990 |
Why?
|
| Platelet Aggregation Inhibitors | 110 | 2025 | 190 | 16.110 |
Why?
|
| Acute Coronary Syndrome | 44 | 2024 | 63 | 11.450 |
Why?
|
| Aspirin | 49 | 2025 | 122 | 8.160 |
Why?
|
| Hemorrhage | 67 | 2025 | 260 | 8.080 |
Why?
|
| Renal Insufficiency, Chronic | 23 | 2023 | 45 | 7.210 |
Why?
|
| Myocardial Infarction | 70 | 2024 | 342 | 7.020 |
Why?
|
| Treatment Outcome | 170 | 2025 | 2286 | 6.920 |
Why?
|
| Risk Assessment | 87 | 2021 | 594 | 5.700 |
Why?
|
| Risk Factors | 142 | 2025 | 2036 | 4.880 |
Why?
|
| Registries | 67 | 2022 | 383 | 4.780 |
Why?
|
| Coronary Thrombosis | 26 | 2021 | 36 | 4.570 |
Why?
|
| Humans | 331 | 2025 | 27145 | 4.550 |
Why?
|
| Aortic Valve Stenosis | 23 | 2023 | 84 | 4.080 |
Why?
|
| Ticlopidine | 24 | 2017 | 34 | 3.950 |
Why?
|
| Aged | 165 | 2025 | 5223 | 3.930 |
Why?
|
| Prasugrel Hydrochloride | 15 | 2024 | 18 | 3.690 |
Why?
|
| Transcatheter Aortic Valve Replacement | 20 | 2023 | 57 | 3.570 |
Why?
|
| Plaque, Atherosclerotic | 20 | 2022 | 48 | 3.550 |
Why?
|
| Drug Therapy, Combination | 50 | 2025 | 204 | 3.400 |
Why?
|
| Middle Aged | 154 | 2025 | 6907 | 3.360 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 26 | 2024 | 34 | 3.310 |
Why?
|
| Diabetes Mellitus | 21 | 2022 | 213 | 3.120 |
Why?
|
| Thrombosis | 23 | 2023 | 147 | 3.020 |
Why?
|
| Male | 177 | 2025 | 13017 | 2.940 |
Why?
|
| Female | 195 | 2025 | 14635 | 2.870 |
Why?
|
| Coronary Angiography | 40 | 2024 | 150 | 2.770 |
Why?
|
| Time Factors | 80 | 2024 | 1572 | 2.700 |
Why?
|
| Stroke | 27 | 2022 | 241 | 2.600 |
Why?
|
| Cardiovascular Diseases | 23 | 2021 | 353 | 2.490 |
Why?
|
| Coronary Vessels | 18 | 2022 | 151 | 2.470 |
Why?
|
| Heart Valve Prosthesis Implantation | 6 | 2023 | 63 | 2.420 |
Why?
|
| Vascular Calcification | 16 | 2020 | 20 | 2.360 |
Why?
|
| Tomography, Optical Coherence | 19 | 2022 | 89 | 2.340 |
Why?
|
| Stents | 28 | 2024 | 116 | 2.300 |
Why?
|
| Myocardial Ischemia | 11 | 2021 | 73 | 2.200 |
Why?
|
| Medication Adherence | 13 | 2022 | 46 | 2.120 |
Why?
|
| Prospective Studies | 61 | 2021 | 1223 | 2.080 |
Why?
|
| Randomized Controlled Trials as Topic | 30 | 2024 | 365 | 2.030 |
Why?
|
| Atrial Fibrillation | 14 | 2022 | 398 | 1.950 |
Why?
|
| Aged, 80 and over | 57 | 2022 | 1939 | 1.920 |
Why?
|
| Aortic Valve | 16 | 2023 | 90 | 1.910 |
Why?
|
| Angioplasty, Balloon, Coronary | 14 | 2019 | 52 | 1.810 |
Why?
|
| Postoperative Complications | 20 | 2021 | 606 | 1.810 |
Why?
|
| United States | 52 | 2023 | 2062 | 1.790 |
Why?
|
| Kidney Diseases | 6 | 2013 | 58 | 1.770 |
Why?
|
| Atherosclerosis | 11 | 2018 | 95 | 1.750 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2023 | 43 | 1.680 |
Why?
|
| Prosthesis Design | 26 | 2022 | 85 | 1.670 |
Why?
|
| Sirolimus | 11 | 2022 | 69 | 1.640 |
Why?
|
| Incidence | 39 | 2021 | 553 | 1.570 |
Why?
|
| Heart Valve Prosthesis | 7 | 2023 | 60 | 1.520 |
Why?
|
| Adenosine | 6 | 2017 | 33 | 1.520 |
Why?
|
| Coronary Restenosis | 8 | 2024 | 21 | 1.350 |
Why?
|
| Retrospective Studies | 50 | 2022 | 2465 | 1.320 |
Why?
|
| Acute Kidney Injury | 9 | 2021 | 73 | 1.300 |
Why?
|
| Coronary Artery Bypass | 9 | 2022 | 68 | 1.300 |
Why?
|
| Coronary Disease | 8 | 2019 | 118 | 1.270 |
Why?
|
| Fibrinolytic Agents | 9 | 2022 | 68 | 1.260 |
Why?
|
| Anticoagulants | 13 | 2022 | 293 | 1.250 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 9 | 2019 | 58 | 1.240 |
Why?
|
| Follow-Up Studies | 37 | 2020 | 989 | 1.240 |
Why?
|
| Prognosis | 34 | 2024 | 762 | 1.220 |
Why?
|
| ST Elevation Myocardial Infarction | 9 | 2019 | 34 | 1.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2020 | 323 | 1.120 |
Why?
|
| Postoperative Hemorrhage | 6 | 2021 | 30 | 1.120 |
Why?
|
| Diabetes Complications | 4 | 2017 | 66 | 1.100 |
Why?
|
| Predictive Value of Tests | 23 | 2022 | 472 | 1.080 |
Why?
|
| C-Reactive Protein | 9 | 2024 | 93 | 1.050 |
Why?
|
| Europe | 18 | 2020 | 97 | 1.040 |
Why?
|
| Everolimus | 10 | 2022 | 16 | 1.030 |
Why?
|
| Antithrombins | 9 | 2020 | 28 | 1.030 |
Why?
|
| Absorbable Implants | 6 | 2022 | 16 | 1.020 |
Why?
|
| Practice Guidelines as Topic | 13 | 2018 | 234 | 1.010 |
Why?
|
| Kaplan-Meier Estimate | 18 | 2021 | 189 | 0.970 |
Why?
|
| Blood Platelets | 10 | 2023 | 203 | 0.970 |
Why?
|
| Peripheral Arterial Disease | 7 | 2024 | 119 | 0.950 |
Why?
|
| Cardiac Catheterization | 6 | 2023 | 112 | 0.950 |
Why?
|
| Ischemia | 2 | 2015 | 83 | 0.920 |
Why?
|
| Guideline Adherence | 4 | 2019 | 91 | 0.890 |
Why?
|
| Lipids | 7 | 2017 | 198 | 0.890 |
Why?
|
| Prevalence | 18 | 2021 | 475 | 0.890 |
Why?
|
| Peptide Fragments | 11 | 2020 | 200 | 0.880 |
Why?
|
| Secondary Prevention | 3 | 2020 | 45 | 0.880 |
Why?
|
| Survival Rate | 23 | 2021 | 412 | 0.880 |
Why?
|
| Calcinosis | 3 | 2018 | 25 | 0.870 |
Why?
|
| Kidney | 5 | 2020 | 275 | 0.870 |
Why?
|
| Glomerular Filtration Rate | 9 | 2020 | 48 | 0.860 |
Why?
|
| Sex Factors | 21 | 2021 | 451 | 0.850 |
Why?
|
| Frailty | 1 | 2023 | 19 | 0.850 |
Why?
|
| Contrast Media | 5 | 2021 | 94 | 0.830 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2018 | 160 | 0.810 |
Why?
|
| Cardiovascular Agents | 5 | 2020 | 22 | 0.810 |
Why?
|
| Balloon Valvuloplasty | 4 | 2015 | 4 | 0.780 |
Why?
|
| Kidney Failure, Chronic | 5 | 2021 | 68 | 0.770 |
Why?
|
| Carotid Artery Diseases | 3 | 2018 | 37 | 0.760 |
Why?
|
| Atherectomy, Coronary | 5 | 2020 | 9 | 0.760 |
Why?
|
| Healthcare Disparities | 3 | 2019 | 89 | 0.760 |
Why?
|
| Blood Vessel Prosthesis Implantation | 3 | 2021 | 36 | 0.760 |
Why?
|
| Thromboembolism | 5 | 2021 | 57 | 0.750 |
Why?
|
| Severity of Illness Index | 22 | 2020 | 447 | 0.750 |
Why?
|
| Mortality | 9 | 2021 | 43 | 0.740 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2023 | 171 | 0.740 |
Why?
|
| Hirudins | 11 | 2020 | 17 | 0.730 |
Why?
|
| Coronary Stenosis | 6 | 2020 | 19 | 0.730 |
Why?
|
| Polymers | 6 | 2022 | 114 | 0.730 |
Why?
|
| Kidney Transplantation | 1 | 2021 | 44 | 0.720 |
Why?
|
| Anemia | 5 | 2020 | 41 | 0.720 |
Why?
|
| Asymptomatic Diseases | 4 | 2018 | 17 | 0.710 |
Why?
|
| Cardiology | 3 | 2023 | 47 | 0.700 |
Why?
|
| Multivariate Analysis | 15 | 2018 | 298 | 0.700 |
Why?
|
| Myocardial Revascularization | 4 | 2018 | 14 | 0.690 |
Why?
|
| Ventricular Fibrillation | 1 | 2019 | 40 | 0.670 |
Why?
|
| Clinical Decision-Making | 6 | 2020 | 61 | 0.660 |
Why?
|
| Cholesterol, LDL | 6 | 2020 | 65 | 0.660 |
Why?
|
| Age Factors | 15 | 2021 | 721 | 0.650 |
Why?
|
| Women's Health | 2 | 2018 | 57 | 0.640 |
Why?
|
| Graft Occlusion, Vascular | 3 | 2016 | 22 | 0.640 |
Why?
|
| Comorbidity | 14 | 2020 | 251 | 0.640 |
Why?
|
| Cause of Death | 11 | 2020 | 66 | 0.640 |
Why?
|
| Heart Diseases | 3 | 2018 | 69 | 0.630 |
Why?
|
| Nutrition Surveys | 2 | 2020 | 27 | 0.630 |
Why?
|
| Proportional Hazards Models | 13 | 2020 | 217 | 0.630 |
Why?
|
| Ultrasonography, Interventional | 7 | 2020 | 38 | 0.620 |
Why?
|
| Cohort Studies | 13 | 2017 | 865 | 0.590 |
Why?
|
| Pyridines | 4 | 2021 | 102 | 0.590 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2019 | 123 | 0.570 |
Why?
|
| Drug Administration Schedule | 13 | 2024 | 218 | 0.570 |
Why?
|
| Heparin | 7 | 2020 | 110 | 0.560 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2016 | 15 | 0.560 |
Why?
|
| Chronic Disease | 9 | 2025 | 265 | 0.550 |
Why?
|
| Platelet Aggregation | 7 | 2021 | 43 | 0.550 |
Why?
|
| Chi-Square Distribution | 11 | 2017 | 144 | 0.530 |
Why?
|
| Angina, Unstable | 7 | 2021 | 19 | 0.520 |
Why?
|
| Hemodynamics | 5 | 2020 | 220 | 0.520 |
Why?
|
| Multimodal Imaging | 5 | 2021 | 22 | 0.500 |
Why?
|
| Propensity Score | 8 | 2020 | 54 | 0.480 |
Why?
|
| Physical Fitness | 1 | 2015 | 61 | 0.480 |
Why?
|
| Receptors, Purinergic P2Y12 | 4 | 2023 | 6 | 0.480 |
Why?
|
| Lipoproteins | 1 | 2015 | 95 | 0.470 |
Why?
|
| Inflammation | 5 | 2022 | 605 | 0.470 |
Why?
|
| Factor Xa Inhibitors | 4 | 2021 | 53 | 0.460 |
Why?
|
| Spectroscopy, Near-Infrared | 4 | 2016 | 74 | 0.460 |
Why?
|
| Renal Dialysis | 4 | 2021 | 52 | 0.460 |
Why?
|
| Databases, Factual | 10 | 2020 | 253 | 0.450 |
Why?
|
| Odds Ratio | 15 | 2020 | 231 | 0.450 |
Why?
|
| Glycated Hemoglobin A | 4 | 2022 | 64 | 0.450 |
Why?
|
| Thiazoles | 3 | 2021 | 50 | 0.450 |
Why?
|
| Body Mass Index | 6 | 2022 | 387 | 0.450 |
Why?
|
| Immunosuppressive Agents | 4 | 2019 | 142 | 0.450 |
Why?
|
| Thrombolytic Therapy | 3 | 2018 | 37 | 0.450 |
Why?
|
| Rural Population | 1 | 2015 | 98 | 0.450 |
Why?
|
| Venous Thromboembolism | 2 | 2018 | 133 | 0.440 |
Why?
|
| Cardiac Valve Annuloplasty | 1 | 2013 | 4 | 0.440 |
Why?
|
| African Americans | 2 | 2019 | 348 | 0.430 |
Why?
|
| Double-Blind Method | 6 | 2020 | 405 | 0.430 |
Why?
|
| Heart Failure | 4 | 2019 | 232 | 0.430 |
Why?
|
| Public Health | 1 | 2014 | 84 | 0.430 |
Why?
|
| Recombinant Proteins | 11 | 2020 | 408 | 0.420 |
Why?
|
| Mitral Valve | 2 | 2023 | 58 | 0.420 |
Why?
|
| Coronary Occlusion | 3 | 2020 | 39 | 0.410 |
Why?
|
| Ventricular Remodeling | 1 | 2012 | 31 | 0.410 |
Why?
|
| Decision Support Techniques | 3 | 2020 | 49 | 0.410 |
Why?
|
| Risk | 7 | 2018 | 133 | 0.410 |
Why?
|
| Preoperative Care | 3 | 2020 | 76 | 0.400 |
Why?
|
| Societies, Medical | 2 | 2016 | 89 | 0.400 |
Why?
|
| Logistic Models | 11 | 2017 | 398 | 0.400 |
Why?
|
| Platelet Function Tests | 7 | 2019 | 24 | 0.400 |
Why?
|
| Obesity | 6 | 2024 | 651 | 0.400 |
Why?
|
| Withholding Treatment | 4 | 2021 | 20 | 0.390 |
Why?
|
| Exome | 5 | 2018 | 30 | 0.390 |
Why?
|
| Quality Improvement | 2 | 2019 | 113 | 0.390 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2020 | 665 | 0.390 |
Why?
|
| Myocardium | 1 | 2012 | 179 | 0.380 |
Why?
|
| Anticholesteremic Agents | 3 | 2017 | 13 | 0.380 |
Why?
|
| Enoxaparin | 1 | 2011 | 37 | 0.370 |
Why?
|
| Artificial Intelligence | 3 | 2022 | 45 | 0.370 |
Why?
|
| Heart Valve Diseases | 2 | 2016 | 26 | 0.370 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 62 | 0.370 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 206 | 0.360 |
Why?
|
| Vascular Surgical Procedures | 2 | 2021 | 54 | 0.360 |
Why?
|
| Recurrence | 9 | 2019 | 316 | 0.360 |
Why?
|
| Health Status | 3 | 2020 | 145 | 0.340 |
Why?
|
| Creatinine | 5 | 2021 | 57 | 0.340 |
Why?
|
| Hospital Mortality | 6 | 2020 | 148 | 0.340 |
Why?
|
| Blood Glucose | 3 | 2024 | 307 | 0.340 |
Why?
|
| Atherectomy | 5 | 2020 | 11 | 0.340 |
Why?
|
| Albuminuria | 1 | 2009 | 23 | 0.340 |
Why?
|
| Biomarkers | 9 | 2020 | 736 | 0.330 |
Why?
|
| Myocardial Perfusion Imaging | 3 | 2013 | 7 | 0.320 |
Why?
|
| Warfarin | 1 | 2010 | 94 | 0.320 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2009 | 64 | 0.320 |
Why?
|
| Fractional Flow Reserve, Myocardial | 2 | 2020 | 7 | 0.320 |
Why?
|
| Carotid Intima-Media Thickness | 3 | 2018 | 10 | 0.310 |
Why?
|
| Vitamin K | 3 | 2021 | 39 | 0.310 |
Why?
|
| Patient Readmission | 2 | 2020 | 103 | 0.300 |
Why?
|
| Angina, Stable | 3 | 2017 | 6 | 0.300 |
Why?
|
| American Heart Association | 3 | 2016 | 21 | 0.300 |
Why?
|
| Cardiovascular System | 2 | 2019 | 39 | 0.300 |
Why?
|
| Exercise | 1 | 2012 | 469 | 0.300 |
Why?
|
| Arteries | 3 | 2021 | 65 | 0.300 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2019 | 57 | 0.300 |
Why?
|
| Disease Management | 2 | 2018 | 85 | 0.290 |
Why?
|
| Computed Tomography Angiography | 3 | 2016 | 24 | 0.290 |
Why?
|
| Aging | 1 | 2015 | 960 | 0.290 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2017 | 128 | 0.280 |
Why?
|
| New York City | 9 | 2020 | 16 | 0.280 |
Why?
|
| Embolic Protection Devices | 2 | 2017 | 7 | 0.280 |
Why?
|
| Diagnostic Imaging | 2 | 2019 | 64 | 0.270 |
Why?
|
| Patient Discharge | 4 | 2021 | 96 | 0.270 |
Why?
|
| Femoral Artery | 3 | 2017 | 58 | 0.270 |
Why?
|
| Neointima | 2 | 2016 | 4 | 0.260 |
Why?
|
| Algorithms | 6 | 2020 | 422 | 0.260 |
Why?
|
| Chest Pain | 3 | 2015 | 25 | 0.260 |
Why?
|
| Adult | 16 | 2021 | 7498 | 0.250 |
Why?
|
| Shock, Cardiogenic | 3 | 2022 | 16 | 0.250 |
Why?
|
| Electrocardiography | 7 | 2020 | 391 | 0.250 |
Why?
|
| Rivaroxaban | 2 | 2016 | 28 | 0.250 |
Why?
|
| Postoperative Care | 3 | 2021 | 67 | 0.240 |
Why?
|
| Health Status Disparities | 2 | 2019 | 60 | 0.240 |
Why?
|
| Ventricular Function, Left | 2 | 2022 | 101 | 0.240 |
Why?
|
| Triage | 2 | 2015 | 32 | 0.240 |
Why?
|
| Genetic Association Studies | 4 | 2017 | 110 | 0.240 |
Why?
|
| Drug Prescriptions | 3 | 2019 | 43 | 0.230 |
Why?
|
| Phenotype | 8 | 2019 | 666 | 0.230 |
Why?
|
| Prosthesis Failure | 1 | 2024 | 21 | 0.230 |
Why?
|
| Tertiary Care Centers | 3 | 2021 | 26 | 0.230 |
Why?
|
| Metabolic Syndrome | 3 | 2020 | 77 | 0.230 |
Why?
|
| Smoking | 4 | 2020 | 466 | 0.230 |
Why?
|
| Sleep Apnea, Central | 1 | 2024 | 13 | 0.220 |
Why?
|
| Heart | 2 | 2023 | 221 | 0.220 |
Why?
|
| Hospitals, High-Volume | 4 | 2017 | 8 | 0.220 |
Why?
|
| Time | 2 | 2020 | 16 | 0.220 |
Why?
|
| Endothelial Progenitor Cells | 2 | 2021 | 15 | 0.220 |
Why?
|
| Exercise Test | 3 | 2013 | 248 | 0.220 |
Why?
|
| Paclitaxel | 3 | 2019 | 184 | 0.220 |
Why?
|
| Mutation | 2 | 2017 | 821 | 0.220 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2015 | 467 | 0.210 |
Why?
|
| Diabetic Angiopathies | 2 | 2014 | 48 | 0.210 |
Why?
|
| Thrombectomy | 2 | 2015 | 26 | 0.210 |
Why?
|
| ROC Curve | 7 | 2020 | 137 | 0.210 |
Why?
|
| Adenosine Monophosphate | 1 | 2023 | 20 | 0.210 |
Why?
|
| Administration, Intravenous | 1 | 2023 | 27 | 0.210 |
Why?
|
| Patient Selection | 6 | 2020 | 143 | 0.210 |
Why?
|
| Blood Pressure | 2 | 2017 | 351 | 0.210 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2013 | 37 | 0.200 |
Why?
|
| Evidence-Based Medicine | 3 | 2018 | 141 | 0.200 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2019 | 12 | 0.200 |
Why?
|
| Sequence Analysis, DNA | 3 | 2018 | 365 | 0.200 |
Why?
|
| Hypoglycemic Agents | 2 | 2020 | 106 | 0.190 |
Why?
|
| 4-Hydroxycoumarins | 1 | 2021 | 1 | 0.190 |
Why?
|
| Health Care Costs | 2 | 2019 | 51 | 0.190 |
Why?
|
| Pilot Projects | 2 | 2020 | 398 | 0.190 |
Why?
|
| Angina Pectoris | 2 | 2022 | 109 | 0.190 |
Why?
|
| Cross-Sectional Studies | 5 | 2020 | 933 | 0.190 |
Why?
|
| Hemoglobin, Sickle | 1 | 2021 | 5 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 591 | 0.180 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2021 | 28 | 0.180 |
Why?
|
| Pacemaker, Artificial | 1 | 2021 | 55 | 0.180 |
Why?
|
| Insulin | 2 | 2020 | 314 | 0.180 |
Why?
|
| Amputation | 1 | 2021 | 42 | 0.180 |
Why?
|
| Cholesterol | 2 | 2019 | 181 | 0.180 |
Why?
|
| Stroke Volume | 3 | 2022 | 111 | 0.180 |
Why?
|
| Hypertension | 4 | 2018 | 305 | 0.180 |
Why?
|
| Risk Adjustment | 2 | 2019 | 8 | 0.180 |
Why?
|
| Lipoproteins, HDL | 1 | 2020 | 41 | 0.180 |
Why?
|
| Lactones | 1 | 2020 | 7 | 0.170 |
Why?
|
| Multifactorial Inheritance | 2 | 2017 | 13 | 0.170 |
Why?
|
| Embolism | 2 | 2017 | 14 | 0.170 |
Why?
|
| Forecasting | 1 | 2020 | 71 | 0.170 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2020 | 26 | 0.170 |
Why?
|
| Vascular Access Devices | 1 | 2019 | 4 | 0.170 |
Why?
|
| Blood | 1 | 2020 | 33 | 0.170 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2020 | 33 | 0.170 |
Why?
|
| Survival Analysis | 4 | 2018 | 279 | 0.170 |
Why?
|
| Primary Prevention | 2 | 2017 | 25 | 0.170 |
Why?
|
| Oxidoreductases | 1 | 2020 | 56 | 0.170 |
Why?
|
| Mutation, Missense | 1 | 2020 | 68 | 0.170 |
Why?
|
| Angioplasty, Balloon | 1 | 2019 | 21 | 0.170 |
Why?
|
| Heart-Assist Devices | 1 | 2020 | 26 | 0.170 |
Why?
|
| Case-Control Studies | 6 | 2019 | 706 | 0.170 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2019 | 24 | 0.170 |
Why?
|
| Mitochondrial Proteins | 1 | 2020 | 71 | 0.170 |
Why?
|
| Genetic Variation | 2 | 2018 | 229 | 0.170 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2019 | 4 | 0.170 |
Why?
|
| Sleep | 1 | 2020 | 101 | 0.170 |
Why?
|
| Patient Care Team | 1 | 2020 | 62 | 0.160 |
Why?
|
| Liver Cirrhosis | 1 | 2020 | 67 | 0.160 |
Why?
|
| Collagen Type III | 2 | 2016 | 3 | 0.160 |
Why?
|
| Coronary Circulation | 1 | 2019 | 30 | 0.160 |
Why?
|
| Fatty Liver | 1 | 2020 | 55 | 0.160 |
Why?
|
| Cholesterol, HDL | 4 | 2015 | 59 | 0.160 |
Why?
|
| Cytochrome P-450 CYP2C19 | 2 | 2016 | 2 | 0.160 |
Why?
|
| Medicine | 1 | 2019 | 22 | 0.160 |
Why?
|
| Computational Biology | 1 | 2020 | 150 | 0.160 |
Why?
|
| Vascular Diseases | 1 | 2020 | 67 | 0.160 |
Why?
|
| Global Health | 4 | 2021 | 43 | 0.160 |
Why?
|
| Bionics | 1 | 2018 | 1 | 0.160 |
Why?
|
| Drug Costs | 1 | 2019 | 17 | 0.160 |
Why?
|
| Cost Savings | 1 | 2019 | 19 | 0.160 |
Why?
|
| Blood Loss, Surgical | 2 | 2018 | 52 | 0.160 |
Why?
|
| Activin Receptors, Type I | 1 | 2018 | 5 | 0.160 |
Why?
|
| Standard of Care | 1 | 2018 | 11 | 0.160 |
Why?
|
| Lipid Metabolism | 3 | 2014 | 122 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 108 | 0.150 |
Why?
|
| Neovascularization, Pathologic | 2 | 2017 | 144 | 0.150 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 4 | 2019 | 13 | 0.150 |
Why?
|
| Brachytherapy | 1 | 2018 | 50 | 0.150 |
Why?
|
| Disease | 1 | 2018 | 15 | 0.150 |
Why?
|
| Sex Distribution | 4 | 2021 | 76 | 0.150 |
Why?
|
| Antibodies | 1 | 2018 | 124 | 0.150 |
Why?
|
| Clinical Protocols | 1 | 2018 | 45 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2017 | 544 | 0.150 |
Why?
|
| Soluble Guanylyl Cyclase | 1 | 2017 | 2 | 0.150 |
Why?
|
| Clonal Evolution | 1 | 2017 | 1 | 0.140 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2017 | 55 | 0.140 |
Why?
|
| Platelet Transfusion | 1 | 2017 | 29 | 0.140 |
Why?
|
| Hematopoiesis | 1 | 2017 | 24 | 0.140 |
Why?
|
| Preoperative Period | 1 | 2017 | 15 | 0.140 |
Why?
|
| Leukocytes | 1 | 2017 | 69 | 0.140 |
Why?
|
| Tissue Scaffolds | 1 | 2018 | 88 | 0.140 |
Why?
|
| Healthy Lifestyle | 1 | 2016 | 3 | 0.140 |
Why?
|
| Thienopyridines | 1 | 2016 | 1 | 0.140 |
Why?
|
| Reproducibility of Results | 5 | 2022 | 751 | 0.140 |
Why?
|
| Alanine Transaminase | 1 | 2016 | 25 | 0.140 |
Why?
|
| Cost of Illness | 1 | 2017 | 51 | 0.130 |
Why?
|
| Nitric Oxide | 1 | 2017 | 152 | 0.130 |
Why?
|
| Hemoglobins | 2 | 2019 | 116 | 0.130 |
Why?
|
| Proton Pump Inhibitors | 1 | 2016 | 26 | 0.130 |
Why?
|
| Endothelium, Vascular | 1 | 2019 | 305 | 0.130 |
Why?
|
| Galactosyltransferases | 1 | 2016 | 16 | 0.130 |
Why?
|
| New York | 4 | 2020 | 17 | 0.130 |
Why?
|
| Multidetector Computed Tomography | 1 | 2016 | 4 | 0.130 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 47 | 0.130 |
Why?
|
| Breast Diseases | 1 | 2016 | 7 | 0.130 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 20 | 0.130 |
Why?
|
| Emergency Service, Hospital | 2 | 2014 | 119 | 0.130 |
Why?
|
| Technetium Tc 99m Sestamibi | 2 | 2013 | 3 | 0.130 |
Why?
|
| Myofibroblasts | 1 | 2016 | 23 | 0.130 |
Why?
|
| Necrosis | 2 | 2017 | 80 | 0.130 |
Why?
|
| Peptide Hormones | 1 | 2016 | 4 | 0.130 |
Why?
|
| Catheter Ablation | 1 | 2018 | 220 | 0.130 |
Why?
|
| Area Under Curve | 4 | 2020 | 94 | 0.130 |
Why?
|
| Triiodobenzoic Acids | 1 | 2015 | 1 | 0.130 |
Why?
|
| Ioxaglic Acid | 1 | 2015 | 2 | 0.130 |
Why?
|
| Apolipoprotein C-III | 1 | 2015 | 12 | 0.130 |
Why?
|
| Proteins | 1 | 2018 | 245 | 0.130 |
Why?
|
| Breast | 1 | 2016 | 54 | 0.130 |
Why?
|
| Point Mutation | 1 | 2016 | 60 | 0.130 |
Why?
|
| Reference Standards | 2 | 2013 | 54 | 0.120 |
Why?
|
| Catheterization, Peripheral | 1 | 2015 | 24 | 0.120 |
Why?
|
| Pulmonary Artery | 1 | 2016 | 68 | 0.120 |
Why?
|
| Radiopharmaceuticals | 2 | 2013 | 69 | 0.120 |
Why?
|
| Fibroblasts | 1 | 2016 | 151 | 0.120 |
Why?
|
| Fibrosis | 2 | 2015 | 121 | 0.120 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 110 | 0.120 |
Why?
|
| Disease Progression | 4 | 2021 | 458 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2022 | 811 | 0.120 |
Why?
|
| Mammography | 1 | 2016 | 79 | 0.120 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2014 | 3 | 0.120 |
Why?
|
| HIV Infections | 1 | 2017 | 149 | 0.120 |
Why?
|
| Thiophenes | 1 | 2014 | 14 | 0.120 |
Why?
|
| beta-Alanine | 1 | 2014 | 12 | 0.120 |
Why?
|
| Dabigatran | 1 | 2014 | 20 | 0.120 |
Why?
|
| Morpholines | 1 | 2014 | 27 | 0.120 |
Why?
|
| Seizures | 1 | 2014 | 46 | 0.120 |
Why?
|
| Benzimidazoles | 1 | 2014 | 29 | 0.120 |
Why?
|
| Pyridones | 1 | 2014 | 33 | 0.120 |
Why?
|
| Developing Countries | 1 | 2014 | 46 | 0.120 |
Why?
|
| Macrophages | 1 | 2017 | 280 | 0.110 |
Why?
|
| Anemia, Hypochromic | 1 | 2014 | 3 | 0.110 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 292 | 0.110 |
Why?
|
| Pyrazoles | 1 | 2014 | 62 | 0.110 |
Why?
|
| Comparative Effectiveness Research | 3 | 2020 | 12 | 0.110 |
Why?
|
| Germany | 3 | 2019 | 24 | 0.110 |
Why?
|
| Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography | 1 | 2013 | 2 | 0.110 |
Why?
|
| Drug Substitution | 1 | 2013 | 5 | 0.110 |
Why?
|
| Poverty | 1 | 2014 | 80 | 0.110 |
Why?
|
| Dyspnea | 2 | 2024 | 25 | 0.110 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2013 | 4 | 0.110 |
Why?
|
| Meningioma | 1 | 2014 | 79 | 0.110 |
Why?
|
| Emergency Medical Services | 1 | 2014 | 79 | 0.110 |
Why?
|
| Endosonography | 1 | 2013 | 36 | 0.110 |
Why?
|
| Prodrugs | 1 | 2013 | 29 | 0.110 |
Why?
|
| Blood Coagulation | 1 | 2014 | 116 | 0.110 |
Why?
|
| Hemostatic Techniques | 1 | 2013 | 14 | 0.110 |
Why?
|
| Suture Techniques | 1 | 2013 | 28 | 0.110 |
Why?
|
| Hospitalization | 1 | 2014 | 193 | 0.110 |
Why?
|
| Health Surveys | 2 | 2011 | 77 | 0.100 |
Why?
|
| Platelet Activation | 1 | 2013 | 54 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 262 | 0.100 |
Why?
|
| Haptoglobins | 1 | 2012 | 21 | 0.100 |
Why?
|
| Sodium Bicarbonate | 1 | 2012 | 5 | 0.100 |
Why?
|
| Overweight | 2 | 2024 | 108 | 0.100 |
Why?
|
| Florida | 3 | 2020 | 54 | 0.100 |
Why?
|
| Heart Arrest | 1 | 2012 | 26 | 0.100 |
Why?
|
| Sodium Chloride | 1 | 2012 | 65 | 0.100 |
Why?
|
| Sensitivity and Specificity | 4 | 2013 | 509 | 0.100 |
Why?
|
| Signal Transduction | 1 | 2017 | 1374 | 0.090 |
Why?
|
| Death | 2 | 2023 | 8 | 0.090 |
Why?
|
| Polysaccharides | 1 | 2011 | 61 | 0.090 |
Why?
|
| Intention to Treat Analysis | 2 | 2021 | 13 | 0.090 |
Why?
|
| Troponin I | 2 | 2024 | 14 | 0.090 |
Why?
|
| Saphenous Vein | 1 | 2010 | 24 | 0.090 |
Why?
|
| Young Adult | 4 | 2020 | 2629 | 0.090 |
Why?
|
| Adolescent | 4 | 2020 | 2991 | 0.090 |
Why?
|
| Genotype | 3 | 2017 | 444 | 0.090 |
Why?
|
| International Normalized Ratio | 1 | 2010 | 27 | 0.090 |
Why?
|
| Hypolipidemic Agents | 1 | 2009 | 20 | 0.080 |
Why?
|
| Systole | 1 | 2009 | 24 | 0.080 |
Why?
|
| Antifibrinolytic Agents | 1 | 2010 | 22 | 0.080 |
Why?
|
| Hospital Costs | 2 | 2020 | 29 | 0.080 |
Why?
|
| Geography | 2 | 2020 | 47 | 0.080 |
Why?
|
| Antihypertensive Agents | 1 | 2009 | 57 | 0.080 |
Why?
|
| Brain | 1 | 2014 | 708 | 0.080 |
Why?
|
| Machine Learning | 2 | 2020 | 81 | 0.080 |
Why?
|
| Postoperative Period | 2 | 2018 | 67 | 0.080 |
Why?
|
| Precision Medicine | 2 | 2019 | 68 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2012 | 630 | 0.070 |
Why?
|
| Bayes Theorem | 2 | 2019 | 95 | 0.070 |
Why?
|
| Rosuvastatin Calcium | 2 | 2018 | 3 | 0.070 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2021 | 28 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 929 | 0.070 |
Why?
|
| Italy | 2 | 2019 | 13 | 0.070 |
Why?
|
| Software | 2 | 2022 | 121 | 0.070 |
Why?
|
| Gene Frequency | 2 | 2018 | 182 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2017 | 52 | 0.070 |
Why?
|
| Genome-Wide Association Study | 2 | 2018 | 238 | 0.070 |
Why?
|
| Alleles | 2 | 2020 | 347 | 0.070 |
Why?
|
| Cross-Over Studies | 2 | 2017 | 132 | 0.060 |
Why?
|
| Observer Variation | 2 | 2016 | 43 | 0.060 |
Why?
|
| Academic Medical Centers | 2 | 2017 | 73 | 0.060 |
Why?
|
| Constriction, Pathologic | 2 | 2016 | 34 | 0.060 |
Why?
|
| Troponin | 1 | 2024 | 2 | 0.060 |
Why?
|
| Drug Resistance | 2 | 2017 | 42 | 0.060 |
Why?
|
| Equipment Design | 2 | 2017 | 211 | 0.060 |
Why?
|
| Actins | 2 | 2016 | 94 | 0.060 |
Why?
|
| Single-Blind Method | 2 | 2014 | 43 | 0.060 |
Why?
|
| Acute Disease | 2 | 2014 | 156 | 0.060 |
Why?
|
| Canada | 1 | 2023 | 59 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2016 | 774 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2014 | 388 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2023 | 103 | 0.050 |
Why?
|
| Phenindione | 1 | 2021 | 1 | 0.050 |
Why?
|
| Aftercare | 1 | 2021 | 32 | 0.050 |
Why?
|
| Pandemics | 1 | 2023 | 176 | 0.050 |
Why?
|
| Morphine | 1 | 2021 | 28 | 0.050 |
Why?
|
| Tunica Intima | 1 | 2020 | 9 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 46 | 0.050 |
Why?
|
| Elective Surgical Procedures | 1 | 2021 | 70 | 0.050 |
Why?
|
| Support Vector Machine | 1 | 2020 | 21 | 0.040 |
Why?
|
| Fentanyl | 1 | 2021 | 33 | 0.040 |
Why?
|
| Loss of Function Mutation | 1 | 2020 | 4 | 0.040 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2020 | 9 | 0.040 |
Why?
|
| Homozygote | 1 | 2020 | 36 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2020 | 21 | 0.040 |
Why?
|
| Dissection | 1 | 2020 | 20 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2021 | 122 | 0.040 |
Why?
|
| Hemorrhagic Disorders | 1 | 2020 | 4 | 0.040 |
Why?
|
| Asia | 1 | 2020 | 20 | 0.040 |
Why?
|
| Chromium | 1 | 2020 | 13 | 0.040 |
Why?
|
| Cobalt | 1 | 2020 | 18 | 0.040 |
Why?
|
| Spain | 1 | 2019 | 14 | 0.040 |
Why?
|
| Patient-Specific Modeling | 1 | 2019 | 1 | 0.040 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2019 | 3 | 0.040 |
Why?
|
| Societies, Scientific | 1 | 2019 | 9 | 0.040 |
Why?
|
| Placebos | 1 | 2019 | 45 | 0.040 |
Why?
|
| Hydrodynamics | 1 | 2019 | 7 | 0.040 |
Why?
|
| Safety | 1 | 2019 | 31 | 0.040 |
Why?
|
| Prosthesis Implantation | 1 | 2019 | 26 | 0.040 |
Why?
|
| Wearable Electronic Devices | 1 | 2019 | 10 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 44 | 0.040 |
Why?
|
| Osmolar Concentration | 1 | 2019 | 25 | 0.040 |
Why?
|
| Consensus | 1 | 2019 | 69 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 43 | 0.040 |
Why?
|
| Bioengineering | 1 | 2019 | 5 | 0.040 |
Why?
|
| Length of Stay | 1 | 2020 | 218 | 0.040 |
Why?
|
| Models, Cardiovascular | 1 | 2019 | 46 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2020 | 163 | 0.040 |
Why?
|
| Stress, Mechanical | 1 | 2019 | 104 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2019 | 33 | 0.040 |
Why?
|
| RNA, Small Cytoplasmic | 1 | 1999 | 63 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2019 | 51 | 0.040 |
Why?
|
| North America | 1 | 2018 | 39 | 0.040 |
Why?
|
| Re-Epithelialization | 1 | 2018 | 5 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 53 | 0.040 |
Why?
|
| Antigens, CD34 | 1 | 2018 | 13 | 0.040 |
Why?
|
| Polypharmacy | 1 | 2018 | 11 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2018 | 28 | 0.040 |
Why?
|
| Morbidity | 1 | 2018 | 58 | 0.040 |
Why?
|
| Simvastatin | 1 | 2018 | 9 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2020 | 153 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 191 | 0.040 |
Why?
|
| Ultrasonography, Doppler | 1 | 2018 | 22 | 0.040 |
Why?
|
| Reoperation | 1 | 2019 | 144 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 80 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2018 | 65 | 0.040 |
Why?
|
| Physicians | 1 | 2019 | 80 | 0.040 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2018 | 3 | 0.040 |
Why?
|
| Patient Safety | 1 | 2018 | 36 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2018 | 47 | 0.040 |
Why?
|
| United Kingdom | 1 | 2018 | 70 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2018 | 166 | 0.040 |
Why?
|
| Ribonucleoproteins | 1 | 1999 | 153 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 240 | 0.040 |
Why?
|
| Protective Factors | 1 | 2017 | 16 | 0.040 |
Why?
|
| Retreatment | 1 | 2017 | 12 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2018 | 64 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2017 | 25 | 0.040 |
Why?
|
| Decision Making | 1 | 2019 | 170 | 0.040 |
Why?
|
| Autoantigens | 1 | 1999 | 212 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 99 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2018 | 93 | 0.040 |
Why?
|
| Popliteal Artery | 1 | 2017 | 10 | 0.030 |
Why?
|
| Liver | 1 | 2020 | 424 | 0.030 |
Why?
|
| Mass Screening | 1 | 2018 | 148 | 0.030 |
Why?
|
| Angiography | 1 | 2017 | 35 | 0.030 |
Why?
|
| Apolipoprotein E2 | 1 | 2016 | 1 | 0.030 |
Why?
|
| Apolipoprotein B-100 | 1 | 2016 | 4 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2017 | 58 | 0.030 |
Why?
|
| Probability | 1 | 2017 | 75 | 0.030 |
Why?
|
| New South Wales | 1 | 2016 | 2 | 0.030 |
Why?
|
| Drug Antagonism | 1 | 2016 | 2 | 0.030 |
Why?
|
| Macular Degeneration | 1 | 2017 | 79 | 0.030 |
Why?
|
| Intracranial Embolism | 1 | 2016 | 6 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2016 | 93 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 91 | 0.030 |
Why?
|
| Network Meta-Analysis | 1 | 2016 | 4 | 0.030 |
Why?
|
| Outpatients | 1 | 2016 | 42 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 2016 | 40 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2016 | 57 | 0.030 |
Why?
|
| Markov Chains | 1 | 2016 | 16 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2016 | 75 | 0.030 |
Why?
|
| Myosin Heavy Chains | 1 | 2016 | 22 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 79 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 201 | 0.030 |
Why?
|
| Angiopoietin-like Proteins | 1 | 2016 | 1 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 188 | 0.030 |
Why?
|
| Vasoconstriction | 1 | 2016 | 45 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2016 | 61 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 163 | 0.030 |
Why?
|
| Research Report | 1 | 2016 | 22 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2016 | 31 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2016 | 59 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2016 | 98 | 0.030 |
Why?
|
| Radial Artery | 1 | 2015 | 21 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2016 | 77 | 0.030 |
Why?
|
| Rupture, Spontaneous | 1 | 2015 | 10 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2016 | 126 | 0.030 |
Why?
|
| Sicily | 1 | 2015 | 1 | 0.030 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 58 | 0.030 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2016 | 67 | 0.030 |
Why?
|
| Platelet Count | 1 | 2016 | 112 | 0.030 |
Why?
|
| Triglycerides | 1 | 2015 | 120 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 369 | 0.030 |
Why?
|
| Random Allocation | 1 | 2015 | 148 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 438 | 0.030 |
Why?
|
| Research Design | 1 | 2016 | 173 | 0.030 |
Why?
|
| Transcriptome | 1 | 2016 | 205 | 0.030 |
Why?
|
| Metaplasia | 1 | 2014 | 4 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2016 | 190 | 0.030 |
Why?
|
| Denmark | 1 | 2014 | 26 | 0.030 |
Why?
|
| Radiography | 1 | 2015 | 201 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2014 | 66 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2017 | 792 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2014 | 48 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2014 | 100 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 240 | 0.030 |
Why?
|
| Causality | 1 | 2013 | 14 | 0.030 |
Why?
|
| Thrombelastography | 1 | 2014 | 46 | 0.030 |
Why?
|
| Myocardial Reperfusion | 1 | 2013 | 5 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 91 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2013 | 119 | 0.030 |
Why?
|
| Metals | 1 | 2013 | 39 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2013 | 58 | 0.030 |
Why?
|
| Automation | 1 | 2013 | 19 | 0.030 |
Why?
|
| Anthropometry | 1 | 2013 | 94 | 0.030 |
Why?
|
| Punctures | 1 | 2013 | 17 | 0.030 |
Why?
|
| Endovascular Procedures | 1 | 2013 | 61 | 0.030 |
Why?
|
| Reference Values | 1 | 2013 | 199 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2012 | 14 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2012 | 20 | 0.030 |
Why?
|
| Apoptosis | 1 | 2016 | 738 | 0.030 |
Why?
|
| Peroxidase | 1 | 2012 | 38 | 0.030 |
Why?
|
| Heme Oxygenase-1 | 1 | 2012 | 36 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2012 | 25 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2012 | 17 | 0.030 |
Why?
|
| Base Sequence | 1 | 2013 | 575 | 0.020 |
Why?
|
| Troponin T | 1 | 2012 | 1 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2012 | 67 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 111 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2012 | 134 | 0.020 |
Why?
|
| Hematologic Agents | 1 | 2011 | 1 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 202 | 0.020 |
Why?
|
| Body Height | 1 | 2011 | 58 | 0.020 |
Why?
|
| Obesity, Abdominal | 1 | 2011 | 4 | 0.020 |
Why?
|
| Mice | 2 | 2017 | 4468 | 0.020 |
Why?
|
| Iron | 1 | 2012 | 107 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2011 | 18 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 247 | 0.020 |
Why?
|
| Minority Groups | 1 | 2011 | 64 | 0.020 |
Why?
|
| Body Weight | 1 | 2011 | 247 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2009 | 31 | 0.020 |
Why?
|
| Animals | 2 | 2017 | 10074 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1999 | 130 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1999 | 75 | 0.010 |
Why?
|
| Immunization | 1 | 1999 | 118 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1999 | 264 | 0.010 |
Why?
|
| Epitopes | 1 | 1999 | 177 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1999 | 204 | 0.010 |
Why?
|
| Autoimmunity | 1 | 1999 | 154 | 0.010 |
Why?
|